{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:14:37Z","timestamp":1792664077952,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.expneurol.2005.02.002","type":"journal-article","created":{"date-parts":[[2005,3,19]],"date-time":"2005-03-19T23:18:26Z","timestamp":1111274306000},"page":"66-75","source":"Crossref","is-referenced-by-count":189,"title":["Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia"],"prefix":"10.1016","volume":"194","author":[{"given":"M.","family":"Lundblad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Usiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Carta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"H\u00e5kansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fisone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Cenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2005.02.002_bib1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/nbdi.1999.0259","article-title":"Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease","volume":"6","author":"Andersson","year":"1999","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2005.02.002_bib2","first-page":"1483","article-title":"Rotation and striatal c-fos expression after repeated, daily treatment with selective dopamine receptor agonists and levodopa","volume":"273","author":"Asin","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2005.02.002_bib3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: potential for new therapies","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat. Rev., Neurosci."},{"key":"10.1016\/j.expneurol.2005.02.002_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1017\/S031716710003849X","article-title":"Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients","volume":"23","author":"Blanchet","year":"1996","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.expneurol.2005.02.002_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","article-title":"Buspirone in levodopa-induced dyskinesias","volume":"17","author":"Bonifati","year":"1994","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2005.02.002_bib6","series-title":"Animal models of movement disorders","first-page":"193","article-title":"Utility of 6-hydroxydopamine lesioned rats in the preclinical screening of novel treatments for Parkinson disease","author":"Cenci","year":"2005"},{"issue":"Suppl. S","key":"10.1016\/j.expneurol.2005.02.002_bib7","first-page":"S98","article-title":"Striatal expression of FosB-related transcription factors in human Parkinson's disease: relation to l-DOPA-induced dyskinesia","volume":"17","author":"Cenci","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2005.02.002_bib8","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nrn877","article-title":"Animal models of neurological deficits: how relevant is the rat?","volume":"3","author":"Cenci","year":"2002","journal-title":"Nat. Rev., Neurosci."},{"key":"10.1016\/j.expneurol.2005.02.002_bib9","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1212\/WNL.50.5_Suppl_5.S17","article-title":"Levodopa therapy: consequences of the nonphysiologic replacement of dopamine","volume":"50","author":"Chase","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2005.02.002_bib10","series-title":"The Cochrane Library","article-title":"Amantadine for dyskinesia in Parkinson's disease (cochrane review)","author":"Crosby","year":"2003"},{"key":"10.1016\/j.expneurol.2005.02.002_bib38","article-title":"Clinically proven antidyskinetic agents are effective in rat model of l-DOPA-induced dyskinesia","volume":"29","author":"Dekundy","year":"2003","journal-title":"Abstr.-Soc. Neurosci."},{"key":"10.1016\/j.expneurol.2005.02.002_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0306-4522(94)90062-0","article-title":"Oral stereotypy induced by amphetamine microinjection into striatum: an anatomical mapping study","volume":"61","author":"Dickson","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2005.02.002_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1460-9568.1996.tb01220.x","article-title":"Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum","volume":"8","author":"Doucet","year":"1996","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2005.02.002_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0006-8993(99)01573-5","article-title":"The axonal arborization of single nigrostriatal neurons in rats","volume":"834","author":"Gauthier","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2005.02.002_bib14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/exnr.2002.8006","article-title":"Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer","volume":"177","author":"Georgievska","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2005.02.002_bib15","first-page":"S90","article-title":"Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates","volume":"47","author":"Jenner","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2005.02.002_bib16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ana.410430415","article-title":"Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys","volume":"43","author":"Kanda","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2005.02.002_bib17","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJM198804073181402","article-title":"Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications","volume":"318","author":"Kish","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2005.02.002_bib18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2005.02.002_bib19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.nbd.2004.01.007","article-title":"A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function","volume":"16","author":"Lundblad","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2005.02.002_bib20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/mds.870090103","article-title":"Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology","volume":"9","author":"Marconi","year":"1994","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2005.02.002_bib21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/syn.10291","article-title":"Bilateral subthalamic nucleus lesion reverses l-DOPA-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats","volume":"51","author":"Marin","year":"2004","journal-title":"Synapse"},{"key":"10.1016\/j.expneurol.2005.02.002_bib22","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(99)00120-8","article-title":"Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease","volume":"353","author":"Merims","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.expneurol.2005.02.002_bib23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.410390504","article-title":"The response to levodopa in Parkinson's disease: imposing pharmacological law and order","volume":"39","author":"Nutt","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2005.02.002_bib24","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1471-1931(00)00031-8","article-title":"Levodopa motor complications in Parkinson's disease","volume":"23","author":"Obeso","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.expneurol.2005.02.002_bib25","first-page":"S13","article-title":"The evolution and origin of motor complications in Parkinson's disease","volume":"55","author":"Obeso","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2005.02.002_bib26","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1212\/WNL.62.1_suppl_1.S17","article-title":"The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits","volume":"62","author":"Obeso","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2005.02.002_bib27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0006-8993(94)90796-X","article-title":"Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration","volume":"662","author":"Papa","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2005.02.002_bib28","series-title":"The mouse brain in stereotaxic coordinates","author":"Paxinos","year":"2001"},{"key":"10.1016\/j.expneurol.2005.02.002_bib29","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ana.410420508","article-title":"Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias","volume":"42","author":"Piccini","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2005.02.002_bib30","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nn1040","article-title":"Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia","volume":"6","author":"Picconi","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.expneurol.2005.02.002_bib31","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s007020070029","article-title":"Comparative effects of repeated administration of dopamine agonists on circling behavior in rats","volume":"107","author":"Prikhojan","year":"2000","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.expneurol.2005.02.002_bib32","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0301-0082(97)00008-7","article-title":"Psychopharmacology of dopamine: the contribution of comparative studies in inbred strains of mice","volume":"51","author":"Puglisi-Allegra","year":"1997","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.expneurol.2005.02.002_bib33","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group","volume":"342","author":"Rascol","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2005.02.002_bib34","series-title":"Central nervous system diseases: innovative animal models from lab to clinic","first-page":"131","article-title":"Intervention strategies for degeneration of dopamine neurons in parkinsonism; optimizing behavioural assessment of outcome","author":"Schallert","year":"2000"},{"key":"10.1016\/j.expneurol.2005.02.002_bib35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0166-4328(01)00309-6","article-title":"Behavioral phenotyping of the MPTP mouse model of Parkinson's disease","volume":"125","author":"Sedelis","year":"2001","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2005.02.002_bib36","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1073\/pnas.76.9.4350","article-title":"Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications","volume":"76","author":"Towbin","year":"1979","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2005.02.002_bib37","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/nbdi.2002.0499","article-title":"l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function","volume":"10","author":"Winkler","year":"2002","journal-title":"Neurobiol. Dis."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488605000506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488605000506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T19:12:06Z","timestamp":1549307526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488605000506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S0014488605000506"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2005.02.002","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}